182 related articles for article (PubMed ID: 17201179)
1. In vitro biocompatibility between mitomycin-C (MMC) and bacillus Calmette-Guerin (BCG).
Mitsogiannis IC; Psaroudaki Z; Perrea D; Paniara O; Melekos MD; Zervas A; Mitropoulos D
Anticancer Res; 2006; 26(6B):4569-73. PubMed ID: 17201179
[TBL] [Abstract][Full Text] [Related]
2. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
Böhle A; Bock PR
Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
[TBL] [Abstract][Full Text] [Related]
3. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
Ojea A; Nogueira JL; Solsona E; Flores N; Gómez JM; Molina JR; Chantada V; Camacho JE; Piñeiro LM; Rodríguez RH; Isorna S; Blas M; Martínez-Piñeiro JA; Madero R;
Eur Urol; 2007 Nov; 52(5):1398-406. PubMed ID: 17485161
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant intravesical instillation for primary T1G3 bladder cancer: BCG versus MMC in Korea.
Cho IC; Kim EK; Joung JY; Seo HK; Chung J; Park WS; Lee KH
Anticancer Res; 2012 Apr; 32(4):1493-8. PubMed ID: 22493392
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
6. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
[TBL] [Abstract][Full Text] [Related]
7. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer.
Gårdmark T; Jahnson S; Wahlquist R; Wijkström H; Malmström PU
BJU Int; 2007 Apr; 99(4):817-20. PubMed ID: 17244282
[TBL] [Abstract][Full Text] [Related]
8. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M
Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955
[TBL] [Abstract][Full Text] [Related]
9. DNA content analysis, expression of Ki-67 and p53 in rat urothelial lesions induced by N-butyl-N-(4-hydroxybutyl) nitrosamine and treated with mitomycin C and bacillus Calmette-Guérin.
Oliveira PA; Palmeira C; Colaço A; de la Cruz LF; Lopes C
Anticancer Res; 2006; 26(4B):2995-3004. PubMed ID: 16886626
[TBL] [Abstract][Full Text] [Related]
10. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G
J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
[TBL] [Abstract][Full Text] [Related]
11. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials.
Sylvester RJ; van der Meijden AP; Witjes JA; Kurth K
J Urol; 2005 Jul; 174(1):86-91; discussion 91-2. PubMed ID: 15947584
[TBL] [Abstract][Full Text] [Related]
12. [Bacillus of Calmette-Guérin immunotherapy: which protocol?].
Saint F
Prog Urol; 2008 May; 18 Suppl 5():S99-104. PubMed ID: 18585635
[TBL] [Abstract][Full Text] [Related]
13. Intravesical bacillus Calmette-Guérin combined with electromotive mitomycin for high-risk superficial bladder cancer.
Bochner BH
Nat Clin Pract Oncol; 2006 Sep; 3(9):474-5. PubMed ID: 16955082
[No Abstract] [Full Text] [Related]
14. Bacillus Calmette-Guerin inhibits apoptosis in human urothelial carcinoma cell lines in response to cytotoxic injury.
Chen F; Zhang G; Cao Y; Payne R; See WA
J Urol; 2007 Nov; 178(5):2166-70. PubMed ID: 17870116
[TBL] [Abstract][Full Text] [Related]
15. Percutaneous sequential bacillus Calmette-Guèrin and mitomycin C for panurothelial carcinomatosis.
Di Stasi SM; Giannantoni A; Stephen RL; Storti L; Attisani F; Sansalone S; Virgili G
Can J Urol; 2005 Dec; 12(6):2895-8. PubMed ID: 16401376
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the combination therapy of bacillus Calmette-Guérin and mitomycin C with the monotherapy for non-muscle-invasive bladder cancer: a meta-analysis.
Lan Y; Liu D; Lin M
Neoplasma; 2016; 63(6):967-976. PubMed ID: 27596297
[TBL] [Abstract][Full Text] [Related]
17. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study.
Kaasinen E; Wijkström H; Malmström PU; Hellsten S; Duchek M; Mestad O; Rintala E;
Eur Urol; 2003 Jun; 43(6):637-45. PubMed ID: 12767365
[TBL] [Abstract][Full Text] [Related]
18. Effects of sequential intravesical administration of mitomycin C and bacillus Calmette-Guérin on the immune response in the guinea pig bladder.
Balemans LT; Vegt PD; Steerenberg PA; De Boer EC; Van Swaaij A; De Vries RE; Van der Meijden AP; Den Otter W
Urol Res; 1994; 22(4):239-45. PubMed ID: 7871637
[TBL] [Abstract][Full Text] [Related]
19. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
Nativ O; Witjes JA; Hendricksen K; Cohen M; Kedar D; Sidi A; Colombo R; Leibovitch I
J Urol; 2009 Oct; 182(4):1313-7. PubMed ID: 19683278
[TBL] [Abstract][Full Text] [Related]
20. Bacillus Calmette-Guérin versus mitomycin C for the treatment of intermediate-risk non-muscle-invasive bladder cancer: the debate continues.
Sylvester RJ
Eur Urol; 2009 Aug; 56(2):266-8; discussion 268-9. PubMed ID: 19427110
[No Abstract] [Full Text] [Related]
[Next] [New Search]